Boston Scientific Goes on a Buying Spree
Executive Summary
Just a couple of years ago, the notion that cardiovascular device companies would begin to build broad franchises or platforms would have been unthinkable. Go tell that to Boston Scientific.
You may also be interested in...
How To Fix A Guidant: Boston Scientific's Tobin Opens Playbook
Boston Scientific CEO Jim Tobin, in a series of addresses, defends his company's decision to spend $27.3 billion on Guidant Inc., warts and all. Defying criticism of the deal, Tobin lays out how Boston Scientific management corrected Guidant's problems--and why the new company will thrive.
American Injectables $10m Investment Bolsters Domestic Production
American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.
EMA Consults On Using Registry Studies As RWE Source
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Need a specific report? 1000+ reports available
Buy Reports